-+ 0.00%
-+ 0.00%
-+ 0.00%

This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Benzinga·11/20/2025 17:14:47
Listen to the news

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • BTIG analyst Ryan Zimmerman upgraded AVITA Medical Inc (NASDAQ:RCEL) from Sell to Neutral. AVITA Medical shares closed at $3.95 on Wednesday. See how other analysts view this stock.
  • Leerink Partners analyst Andrew Berens upgraded Agios Pharmaceuticals Inc (NASDAQ:AGIO) from Market Perform to Outperform and cut the price target from $40 to $34. Agios Pharmaceuticals shares closed at $22.34 on Wednesday. See how other analysts view this stock.
  • Morgan Stanley analyst Michael Cyprys upgraded Nasdaq Inc (NASDAQ:NDAQ) from Equal-Weight to Overweight and raised the price target from $97 to $110. Nasdaq shares closed at $86.91 on Wednesday. See how other analysts view this stock.
  • Barclays analyst Alex Scott upgraded Marsh & McLennan Companies Inc (NYSE:MMC) from Equal-Weight to Overweight and lowered the price target from $221 to $206. Marsh & McLennan closed at $177.33 on Wednesday. See how other analysts view this stock.
  • William Blair analyst Louie DiPalma upgraded the rating for Parsons Corp (NYSE:PSN) from Market Perform to Outperform. Parsons shares closed at $82.64 on Wednesday. See how other analysts view this stock.

Considering buying RCEL stock? Here’s what analysts think:

Read This Next:

Photo via Shutterstock